Elicio Therapeutics collaborates with Moffitt Cancer Center


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ avenue-improving-outcomes-lymphoma-patients-treated-gene-engineered-t-cells
Elicio Therapeutics and Moffitt Collaborate to study AMP-CD19 in combination with CD19 CAR T cells

Elicio Therapeutics, a next-generation immuno-oncology company, announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicio’s CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells. The research will be led by Marco Davila, M.D., a Ph.D. associate member of the Blood and Marrow Transplant and Cellular Immunotherapies Department and Medical Director of Cell Therapies at Moffitt.

“Despite high initial response rates, patients with B-cell malignancies have limited durable long-term disease control,” said Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer. “We are excited to work with Dr Davila, a pioneer and expert in cell therapy for hematologic malignancies, to study the pharmacology of the combination of AMP-CD19 with CD19 CAR T cells. Dr Davila’s laboratory is uniquely positioned to evaluate lymph node targeted immunotherapy since his team evaluates CD19+ malignancies in mice with a normal immune system and normal lymph nodes, a great advantage over more common mouse models conducted in immunosuppressed mice. Positive results would set the stage for clinical trials combining AMP-CD19 with marketed CD19 CAR T cells to increase response rate and durability.”

“Our research, as well as research by other groups, suggest one avenue for improving outcomes for lymphoma patients treated with gene-engineered T cells is to combine this therapy with other agents to enhance response. We believe the highly novel AMP vaccine holds great promise as a combination to increase the efficacy of T cells targeted to B cell malignancies and look forward to developing and evaluating this therapy at Moffitt,” said Dr Davila.

The AMP-CD19 is a CAR binding peptide modified to traffic into lymph nodes for display on native immune cells. AMP-CD19 can activate engineered T cells, enhance their persistence, and proliferation, as well as enhance their activity in the treatment of B-cell malignancies including diffuse large B cell lymphoma (DLBCL) and acute lymphocytic leukaemia (ALL).

The AMP modification reprograms the biodistribution of peptides by the addition of an albumin-binding and cell membrane insertion domain, which results in improved trafficking into lymph nodes where dendritic cells take in the peptides and present them to the CAR T receptors on the surface of T cells.

Elicio is broadly developing AMP technologies, with ELI-002 targeting solid tumours with mutated KRAS in oncology, the universal adjuvant ELI-004 (AMP-CpG) enhancing efficacy across oncology and infectious disease applications, and discovery programs identifying solid tumour AMP CAR T combinations. In addition, the combination of both Elicio’s Amphiphiles (AMPs) with CAR-Ts led to the synergy that enhanced solid tumour CAR T therapy in mice.

Tags : #ElicioTherapeutics #MoffittCancerCenter #MarcoDavila #ChristopherHaqq #CancerTreatment

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026